Long-Term Follow-Up and Immunomonitoring of Relapsing Type 1 Autoimmune Pancreatitis Treated With Rituximab.
Journal
Pancreas
ISSN: 1536-4828
Titre abrégé: Pancreas
Pays: United States
ID NLM: 8608542
Informations de publication
Date de publication:
01 05 2022
01 05 2022
Historique:
pubmed:
15
7
2022
medline:
19
8
2022
entrez:
14
7
2022
Statut:
ppublish
Résumé
To evaluate the efficacy and safety of rituximab in relapsing type 1 autoimmune pancreatitis especially the long-term clinical and immunologic impacts. All consecutive patients with type 1 autoimmune pancreatitis were retrospectively included. The rituximab protocol was induction therapy of 375 mg·m -2 intravenous weekly for 4 weeks, followed by 500 mg intravenous every 6 months for 2 years. The follow-up included clinical examinations, biological tests, positron emission tomography scan, and immunomonitoring of lymphocyte CD 19+. Among the 43 patients included, 15 received rituximab induction therapy, followed by maintenance in 10 cases because of 1 or more relapses after steroids (whether or not followed by immunosuppressants) and multiple organ involvement. All patients had a clinical, biological and morphological response, a deep and persistent drop in serum immunoglobulin G4 levels, an extinction of both pancreatic and extra pancreatic hypermetabolic positron emission tomography scan signals, and a depletion of B lymphocyte CD19+. No relapse occurred during the follow-up (62.8 ± standard error of the mean of 11.1 months). Rituximab is an effective treatment for type 1 autoimmune pancreatitis that provides a rapid strong clinical, biological, and morphological response, which persists after discontinuation without any safety issues.
Identifiants
pubmed: 35835119
doi: 10.1097/MPA.0000000000002048
pii: 00006676-202205000-00007
doi:
Substances chimiques
Immunologic Factors
0
Rituximab
4F4X42SYQ6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
452-462Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Shimosegawa T, Chari ST, Frulloni L, et al. International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology. Pancreas . 2011;40:352–358.
Sandrasegaran K, Menias CO. Imaging in autoimmune pancreatitis and immunoglobulin G4-related disease of the abdomen. Gastroenterol Clin N Am . 2018;47:603–619.
Madhani K, Farrell JJ. Autoimmune pancreatitis: an update on diagnosis and management. Gastroenterol Clin N Am . 2016;45:29–43.
Okazaki K, Uchida K, Sumimoto K, et al. Autoimmune pancreatitis: pathogenesis, latest developments and clinical guidance. Ther Adv Chronic Dis . 2014;5:104–111.
Nagpal SJS, Sharma A, Chari ST. Autoimmune pancreatitis. Am J Gastroenterol . 2018;113:1301.
Lorenzo D, Maire F, Stefanescu C, et al. Features of autoimmune pancreatitis associated with inflammatory bowel diseases. Clin Gastroenterol Hepatol . 2018;16:59–67.
Majumder S, Takahashi N, Chari ST. Autoimmune pancreatitis. Dig Dis Sci . 2017;62:1762–1769.
Esposito I, Hruban RH, Verbeke C, et al. Guidelines on the histopathology of chronic pancreatitis. Recommendations from the working group for the international consensus guidelines for chronic pancreatitis in collaboration with the International Association of Pancreatology, the American pancreatic association, the Japan Pancreas Society, and the European pancreatic Club. Pancreatology . 2020;20:586–593.
Uchida K, Okazaki K. Clinical and pathophysiological aspects of type 1 autoimmune pancreatitis. J Gastroenterol . 2018;53:475–483.
Okazaki K, Uchida K. Current perspectives on autoimmune pancreatitis and IgG4-related disease. Proc Jpn Acad Ser B Phys Biol Sci . 2018;94:412–427.
Okazaki K, Chari ST, Frulloni L, et al. International consensus for the treatment of autoimmune pancreatitis. Pancreatology . 2017;17:1–6.
Madhani K, Farrell JJ. Management of autoimmune pancreatitis. Gastrointest Endosc Clin N Am . 2018;28:493–519.
Stone JH, Zen Y, Deshpande V. IgG4-related disease. N Engl J Med . 2012;366:539–551.
Hart PA, Zen Y, Chari ST. Recent advances in autoimmune pancreatitis. Gastroenterology . 2015;149:39–51.
Kawano M, Saeki T, Nakashima H, et al. Proposal for diagnostic criteria for IgG4-related kidney disease. Clin Exp Nephrol . 2011;15:615–626.
Kellum JA, Lameire N; KDIGO AKI Guideline Work Group. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (part 1). Crit Care . 2013;17:204.
Thevenot A, Bournet B, Otal P, et al. Endoscopic ultrasound and magnetic resonance cholangiopancreatography in patients with idiopathic acute pancreatitis. Dig Dis Sci . 2013;58:2361–2368.
Geetha D, Jefferson JA. ANCA-associated vasculitis: core curriculum 2020. Am J Kidney Dis . 2020;75:124–137.
Paul F, Cartron G. Infusion-related reactions to rituximab: frequency, mechanisms and predictors. Expert Rev Clin Immunol . 2019;15:383–389.
Miyoshi H, Uchida K, Taniguchi T, et al. Circulating naïve and CD4 + CD25high regulatory T cells in patients with autoimmune pancreatitis. Pancreas . 2008;36:133–140.
Bensalem A, Mulleman D, Thibault G, et al. CD4+ count-dependent concentration-effect relationship of rituximab in rheumatoid arthritis. Br J Clin Pharmacol . 2019;85:2747–2758.
Hart PA, Topazian MD, Witzig TE, et al. Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience. Gut . 2013;62:1607–1615.
Soliman H, Vullierme MP, Maire F, et al. Risk factors and treatment of relapses in autoimmune pancreatitis: rituximab is safe and effective. United European Gastroenterol J . 2019;7:1073–1083.
Campochiaro C, Della-Torre E, Lanzillotta M, et al. Long-term efficacy of maintenance therapy with rituximab for IgG4-related disease. Eur J Intern Med . 2020;74:92–98.
Backhus J, Neumann C, Perkhofer L, et al. A follow-up study of a European IgG4-related disease cohort treated with rituximab. J Clin Med . 2021;10:1329.
van Vollenhoven RF, Fleischmann RM, Furst DE, et al. Longterm safety of rituximab: final report of the rheumatoid arthritis global clinical trial program over 11 years. J Rheumatol . 2015;42:1761–1766.
Deshayes S, Khellaf M, Zarour A, et al. Long-term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: results at 5 years from the French prospective registry ITP-ritux. Am J Hematol . 2019;94:1314–1324.
Salzer J, Svenningsson R, Alping P, et al. Rituximab in multiple sclerosis: a retrospective observational study on safety and efficacy. Neurology . 2016;87:2074–2081.
Löhr JM, Beuers U, Vujasinovic M, et al. European guideline on IgG4-related digestive disease - UEG and SGF evidence-based recommendations. United European Gastroenterol J . 2020;8:637–666.
Kamisawa T, Okazaki K, Kawa S, et al. Amendment of the Japanese consensus guidelines for autoimmune pancreatitis, 2013 III. Treatment and prognosis of autoimmune pancreatitis. J Gastroenterol . 2014;49:961–970.
Matsubayashi H, Ishiwatari H, Imai K, et al. Steroid therapy and steroid response in autoimmune pancreatitis. Int J Mol Sci . 2019;21:257.
Topazian M, Witzig TE, Smyrk TC, et al. Rituximab therapy for refractory biliary strictures in immunoglobulin G4-associated cholangitis. Clin Gastroenterol Hepatol . 2008;6:364–366.
Khosroshahi A, Bloch DB, Deshpande V, et al. Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease. Arthritis Rheum . 2010;62:1755–1762.
Carruthers MN, Topazian MD, Khosroshahi A, et al. Rituximab for IgG4-related disease: a prospective, open-label trial. Ann Rheum Dis . 2015;74:1171–1177.
Ebbo M, Grados A, Samson M, et al. Long-term efficacy and safety of rituximab in IgG4-related disease: data from a French nationwide study of thirty-three patients. PLoS One . 2017;12:e0183844.
De Marchi G, de Pretis N, Gabrieletto EM, et al. Rituximab as maintenance therapy in type 1 autoimmune pancreatitis: an Italian experience. Pancreas . 2021;50:1363–1367.
Lanzillotta M, Vinge-Holmquist O, Overbeek KA, et al. PrescrAIP: A pan-European study on current treatment regimens of auto-immune pancreatitis. Front Med (Lausanne) . 2020;7:408.